The warning comes after a report of a patient who experienced significant liver injury symptoms after about 40 days of use, according to a Sept. 12 news release from the agency.
An Astellas spokesperson told Becker’s, “Astellas remains dedicated to ensuring Veozah is accessible for appropriate patients who may benefit from a non-hormonal treatment option proven to reduce the frequency and severity of moderate to severe vasomotor symptoms (VMS) due to menopause.”
The FDA has updated the prescribing information for Veozah, advising more frequent liver blood testing during the first months of treatment. Healthcare providers are also instructed to perform regular liver function tests before and during treatment as well as educate patients about risks.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
